Babaeski State Hospital, Emergency Unit, Babaeski, Kırklareli, Turkey.
Department of Medical Nursing, Faculty of Health Sciences, Trakya University, Edirne, Turkey.
Support Care Cancer. 2024 Aug 20;32(9):597. doi: 10.1007/s00520-024-08812-9.
This study aimed to evaluate the severity of oral mucositis and the contributing factors among cancer patients undergoing chemotherapy.
This study was planned cross-sectional. The study was conducted at a medical oncology clinic between January and July 2022. The sample consisted of 245 patients with cancer receiving chemotherapy. Data were collected using a personal, oral health and disease-related characteristics questionnaire and the World Health Organization Oral Mucositis Assessment Scale by researchers. Intraoral examination of the patients was carried out by researchers. The data were analyzed by independent-sample t-tests, Chi-square tests, paired-sample t-tests, and multivariate logistic regression (p < 0,05).
The patients had mean age 62.31 ± 10.70. Patients of 32.7% were with lung cancer. 52%of the patients (n = 128) receiving chemotherapy developed oral mucositis. The independent variables the presence chronic disease(OR:1.85), chemotherapy protocol (OR:3.52) and the dependent variables ECOG performance score (OR:2.25) were variable that affected the development of oral mucositis (p < 0.05). Patients of 35.5% were oral mucositis score of 1. Patients those who had breast cancer, who received doxorubicin or cyclophosphamide chemotherapy protocols, and who had previously developed oral mucositis were found to have a higher rate of oral mucositis (p < 0.05). In addition, oral mucositis was more prevalent in patients with chronic diseases other than cancer (57%), those who used medication continuously (57.2%), those with oral and dental diseases (56.9%), those who had dental check-ups before cancer treatment (79.2%), and those who had information about oral mucositis(70.2%) (p < 0.05).
In conclusion, nearly half of the patients (52%, n = 128) receiving chemotherapy developed oral mucositis and of all patients of 35.5% had an oral mucositis score of 1 in the second round of chemotherapy. Patients those who had breast cancer, who received doxorubicin or cyclophosphamide chemotherapy protocols, and who had previously developed oral mucositis were found to have a higher rate of oral mucositis.
本研究旨在评估接受化疗的癌症患者的口腔黏膜炎严重程度及其影响因素。
本研究为计划的横断面研究。研究于 2022 年 1 月至 7 月在一家肿瘤内科诊所进行。研究对象为 245 名接受化疗的癌症患者。研究人员采用个人基本情况、口腔健康及疾病相关特征问卷和世界卫生组织口腔黏膜炎评估量表收集数据,并由研究人员对患者进行口腔检查。采用独立样本 t 检验、卡方检验、配对样本 t 检验和多因素 logistic 回归分析(p<0.05)。
患者的平均年龄为 62.31±10.70 岁。32.7%的患者患有肺癌。52%(n=128)接受化疗的患者发生口腔黏膜炎。影响口腔黏膜炎发生的独立变量为慢性病的存在(OR:1.85)、化疗方案(OR:3.52)和 ECOG 表现评分(OR:2.25)(p<0.05)。35.5%的患者口腔黏膜炎评分为 1。患有乳腺癌、接受多柔比星或环磷酰胺化疗方案以及既往发生过口腔黏膜炎的患者口腔黏膜炎发生率更高(p<0.05)。此外,患有非癌症慢性病(57%)、持续用药(57.2%)、口腔和牙齿疾病(56.9%)、癌症治疗前进行牙科检查(79.2%)和了解口腔黏膜炎信息(70.2%)的患者口腔黏膜炎更为常见(p<0.05)。
接受化疗的患者中,近一半(52%,n=128)发生口腔黏膜炎,且所有患者中有 35.5%在第二轮化疗中口腔黏膜炎评分为 1。患有乳腺癌、接受多柔比星或环磷酰胺化疗方案以及既往发生过口腔黏膜炎的患者口腔黏膜炎发生率更高。